$173 Million Launch for Watertown’s Marrow Therapeutics Targets Sickle Cell Disease

Watertown's Marrow Therapeutics launched Tuesday, Nov. 17, with $173 million for a bone marrow drug for sickle cell and beta thalassemia. What we know.

Share this article

Featured photo: Normal and sickle-shaped red blood cells under a microscope (file photo). Photo: Gregory Kato, Wikimedia Commons, CC BY-SA 4.0.

Marrow Therapeutics, a Watertown startup developing drugs aimed at the bone marrow to treat severe blood disorders, launched on Tuesday, Nov. 17, with $173 million in combined Series A and Series B funding. Its lead drug candidate is meant to treat both sickle cell disease and beta thalassemia.[1]

$173M
combined Series A and B funding
$120M
Series B, led by OrbiMed
$53M
Series A, co-led by Scion and venBio
MAR-101
lead drug, not yet in human trials

Related: Vertex Raises 2026 Forecast on $3.44 Billion Quarter as Crinetics Costs Cut Profit 40%.

Advertisement

The money

The $53 million Series A was co-led by Scion Life Sciences and venBio. The $120 million Series B was led by OrbiMed, with all of the Series A investors returning and new money from RTW Investments, Surveyor Capital (a Citadel company), Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments.[1] The Series B accounts for about 69% of the total (TBR calculation).

Scion formed and incubated Marrow in 2024, and the Series A closed early the following year. The company did not announce that round at the time because it was still securing patent protection for its technology before a formal launch, chief executive Romesh Subramanian told MedCity News.[2]

Who is running it

Subramanian previously served as CEO and chief scientific officer of Dyne Therapeutics in Waltham.[2] Tim Weeden is chief scientific officer, John Najim is chief operating officer and chief technology officer, and Gavriel Mullokandov is a founder and vice president of corporate development. Art Levin, founding chief scientific officer of Avidity Biosciences, joined the board, and Stuart Orkin of Harvard Medical School and Boston Children’s Hospital joined the scientific advisory board.[1] OrbiMed general partner Mona Ashiya praised what she called the company’s “pipeline in a product” strategy in the launch announcement.[1]

How the drug is supposed to work

Marrow’s drugs pair an engineered antibody with a drug payload. The antibody binds to the transferrin receptor, which cells use to take in iron, and carries the payload into bone marrow cells.[1] Blood-forming cells need large amounts of iron, and Subramanian told MedCity News that each red blood cell and progenitor cell in the marrow can carry as many as 500,000 of these receptors. “So really it’s kind of a Trojan horse,” he said.[2]

For MAR-101, the payload is a short strand of RNA that lowers levels of BCL11A, a genetic switch that keeps fetal hemoglobin turned off after infancy. Turning fetal hemoglobin back on is the same target used by Casgevy, the CRISPR gene therapy from Vertex Pharmaceuticals and CRISPR Therapeutics, which requires removing a patient’s cells, editing them in a lab and giving chemotherapy when the cells are returned.[2][3] Marrow says its approach is designed to avoid the safety, manufacturing and access problems of earlier genetic medicines.[1] The key engineering problem, Subramanian said, was finding an antibody that binds the receptor without blocking iron uptake and causing anemia.[3]

What the company claims so far

There is no human data yet. MAR-101 is in IND-enabling studies, the preclinical work needed before the FDA can allow a clinical trial.[1] The company says the drug looked as good as gene therapy in human cells in a dish and was many times as effective as hydroxyurea, the common sickle cell pill, in monkeys. “We expect it to be as good as [gene therapy] in patients,” Subramanian said, adding that this remains to be proven.[3]

Advertisement

The goal is a dose every few weeks rather than a one-time procedure, and Subramanian said Marrow can make the drug cheaply enough to be useful in Africa, Southeast Asia and the Middle East. Gene therapy is not available in sub-Saharan Africa, where the most sickle cell patients live.[3] MedCity News reported the company is developing a room-temperature version patients could inject at home.[2]

What happens next

The timeline is unclear. STAT, via The Boston Globe, reported that Marrow is doing the studies needed to start a human trial next year, and that it is weighing early studies in the U.S. or China.[3] Scion co-founder Aaron Kantoff said in the launch release that he expects Marrow to move its programs into the clinic within about a year.[1] But Subramanian declined to give MedCity News a timeline beyond saying the company would get there as soon as it is feasible.[2] For more on local companies, see our Boston business and finance coverage.

Our Take

Opinion: A $173 million launch for a company with no human data is a strong vote of investor confidence in Greater Boston biotech at a time when many local firms are cutting staff. The pitch, a cheaper, repeat-dose alternative to gene therapy, is compelling, but until MAR-101 is tested in people, the claims that it can match gene therapy are a hypothesis, not a result.

Sources

  1. Business Wire (Marrow Therapeutics release): Marrow Therapeutics Launches With $173 Million to Develop Genetic Medicines for Bone Marrow Disorders (Nov. 17, 2026)
  2. MedCity News: Marrow Therapeutics Unveils $173M for ‘Trojan Horse’ Delivery of Blood Disorder Drugs (Nov. 17, 2026)
  3. STAT, via The Boston Globe: With $173 million, new Watertown startup takes aim at sickle cell (Nov. 18, 2026)

About the reporter: Michael Haverford is an AI reporter covering business, finance and technology for The Boston Report. This article was produced with AI under our editorial policy. Read our AI and media disclosure.

Read next in Boston Local News

Get The Boston Report Briefing

Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.

Free. We never sell your address. Privacy policy

Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Sign up